ArticleInternational journal of impotence research2026
Astaxanthin mitigates radiation-induced erectile dysfunction: protective effects on corpus cavernosum in a rat model.
Article in International journal of impotence research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Quercetin alleviates radiation-induced erectile dysfunction by modulating oxidative stress and apoptosis through the Nrf2/HO-1 pathway.European journal of medical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this study was to evaluate the effects of ionizing radiation (iR) on corpus cavernosum and the potential of astaxanthin (AST) in preventing radiation-induced erectile dysfunction (RiED). Male Wistar Albino rats (10-12 week, 250-300 g) were divided-into four groups: sham (SH, n = 8), radiotherapy (RT, n = 8), vehicle-administered (olive oil (OO); RT + OO, n = 12), and astaxanthin (RT + AST, n = 12). The RT-group received 12-Gy prostate-targeted iR. The vehicle-administered (OO) group received iR with daily 1 ml OO via oral gavage, while the AST-group received iR with 50 mg/kg AST dissolved in OO. After the treatment-period (12-week), intracavernosal pressure to mean arterial pressure (ICP/MAP) ratios in the RT [0.28(0.14-0.65)] and OO groups [0.26(0.19-0.64)] were significantly lower than in the SH [0.6(0.43-0.72)] and AST [0.53(0.35-0.64)] groups (p < 0.05). iR caused narrowing of the cavernous sinusoids (RT:95.38 (84.62-110.05) vs SH:132.33 (113.27-155.86), AST:124.44 (112.11-131.97) µm, p < 0.001). Alpha smooth muscle actin (SH:165 (136.25-188.75) vs RT:100 (87.5-112.5), AST:137.5 (107.5-155), p < 0.001), endothelial nitric-oxide synthase (NOS) (SH:127.5 (115-167.5) vs RT:92.5 (81.25-98.75), AST:115 (86.25-128.75), p = 0.002) and neuronal NOS (SH:152.5 (133.75-163.75) vs RT:95 (81.25-103.75), AST:135 (125-140), p < 0.001) were diminished in the RT-group and preserved in the AST-group according to immunohistochemical scoring. Biochemical measurements of the corpus cavernosum revealed that the level of cGMP was significantly higher (93.15 (71.22-103.38) vs 70.8 (65-72.35) pmol/ml) in the AST-group, while lipid peroxidation was significantly higher (32.38 (29.07-36.98) vs 20.14 (17.85-21.04) nmol.mda/g) in the RT-group (p = 0.004, p < 0.001). This trial showed that AST preserved ICP/MAP values and histopathological-biochemical parameters after exposure to iR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.